Literature DB >> 15754294

Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.

Ruth Birbe1, Juan P Palazzo, Rhonda Walters, David Weinberg, Stephanie Schulz, Scott A Waldman.   

Abstract

Gastrointestinal (GI) tumors continue to be major causes of cancer-related mortality, in part, reflecting metastases that escape detection by histopathology. Moreover, although approximately 10% of carcinomas arise from unknown locations, these tumors frequently originate in the GI tract. Guanylyl cyclase C (GC-C) is a receptor selectively expressed by intestinal epithelial cells whose persistent expression by colorectal carcinomas and ectopic expression by adenocarcinomas of the upper GI tract suggest its use as a marker for GI malignancies. Here, expression of GC-C protein, identified by immunohistochemistry, was examined in tissues and tumors arising from the human GI tract. Guanylyl cyclase C protein was expressed by epithelial cells from the duodenum to the rectum, but not by those in normal esophagus and stomach. Expression was retained in tubular adenomas, inflammatory bowel disease, premalignant lesions, and in primary and metastatic adenocarcinomas from the colon, including metastases to lymph nodes and liver. Moreover, GC-C was ectopically expressed in all cases of dysplasia and adenocarcinomas arising from intestinal metaplasia in esophagus and stomach. Thus, GC-C appears to be an immunohistochemical marker for identifying adenocarcinomas of unknown origin, metastases in patients undergoing staging for GI adenocarcinomas, and intestinal metaplasia, dysplasia, and tumors arising therein in the upper GI tract.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754294     DOI: 10.1016/j.humpath.2004.12.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  67 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

3.  Sex modulates intestinal transformation by the tumor-suppressor GCC.

Authors:  Peng Li; Stephanie Schulz; Giovanni M Pitari; Scott A Waldman
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 4.  Membrane guanylyl cyclase receptors: an update.

Authors:  David L Garbers; Ted D Chrisman; Phi Wiegn; Takeshi Katafuchi; Joseph P Albanesi; Vincent Bielinski; Barbara Barylko; Margaret M Redfield; John C Burnett
Journal:  Trends Endocrinol Metab       Date:  2006-06-30       Impact factor: 12.015

Review 5.  Progress in the development of prognostic and predictive markers for gastrointestinal malignancies.

Authors:  Crystal S Denlinger; Steven J Cohen
Journal:  Curr Treat Options Oncol       Date:  2007-10

Review 6.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 7.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

8.  Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Authors:  Adam E Snook; Michael S Magee; Stephanie Schulz; Scott A Waldman
Journal:  Eur J Immunol       Date:  2014-05-21       Impact factor: 5.532

Review 9.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

10.  Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases.

Authors:  Heather N Tinsley; Gary A Piazza
Journal:  Curr Colorectal Cancer Rep       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.